Free Trial

Outlook Therapeutics (OTLK) Insider Trading & Ownership

Outlook Therapeutics logo
$5.13 -0.15 (-2.84%)
(As of 10:25 AM ET)

Outlook Therapeutics (NASDAQ:OTLK) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.40%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$50,695.24
Number Of
Insiders Selling
(Last 12 Months)
0
Get OTLK Insider Trade Alerts

Want to know when executives and insiders are buying or selling Outlook Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

OTLK Insider Buying and Selling by Quarter

Outlook Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2024Lawrence A KenyonCFOBuy5,000$5.69$28,450.00  
3/28/2024Yezan Munther HaddadinDirectorBuy1,882$11.82$22,245.24  
(Data available from 1/1/2013 forward)

OTLK Insider Trading Activity - Frequently Asked Questions

The list of insiders at Outlook Therapeutics includes C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Lawrence A Kenyon, Terry Dagnon, and Yezan Munther Haddadin. Learn more on insiders at OTLK.

3.40% of Outlook Therapeutics stock is owned by insiders. Learn more on OTLK's insider holdings.

The following insiders have purchased OTLK shares in the last 24 months: Lawrence A Kenyon ($28,450.00), and Yezan Munther Haddadin ($22,245.24).

Insiders have purchased a total of 6,882 OTLK shares in the last 24 months for a total of $50,695.24 bought.

The following insiders have sold OTLK shares in the last 24 months: Jeff Evanson ($161,532.40), and Terry Dagnon ($592,800.00).

Insiders have sold a total of 32,520 Outlook Therapeutics shares in the last 24 months for a total of $754,332.40 sold.

Outlook Therapeutics Key Executives



This page (NASDAQ:OTLK) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners